<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572933</url>
  </required_header>
  <id_info>
    <org_study_id>1042-CDD-3001</org_study_id>
    <secondary_id>2018-001180-23</secondary_id>
    <nct_id>NCT03572933</nct_id>
  </id_info>
  <brief_title>Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder</brief_title>
  <acronym>Marigold</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone
      therapy compared to placebo for the treatment of seizures in children and young adults with
      genetically confirmed CDKL5 gene mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Marigold Study is a global, double-blind, placebo-controlled, Phase 3 clinical trial that
      will enroll approximately 70 patients between the ages of 2 and 21 with a confirmed
      disease-related CDKL5 gene variant. Patients will undergo a baseline period before being
      randomized to receive, in addition to their existing anti-seizure treatment, either
      ganaxolone or placebo for 17 weeks. Following the treatment period, all patients that meet
      certain eligibility requirements will have the opportunity to receive ganaxolone in the open
      label phase of the study. The study's primary efficacy endpoint is percent reduction in
      seizures. Secondary outcome measures will include non-seizure-related endpoints to capture
      certain behavioral and sleep disturbances that have been seen in previous clinical studies
      with ganaxolone.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 30, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The double-blind phase will randomize subjects to adjunctive ganaxolone or placebo at a 1:1 ratio to standard of care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in 28-day seizure frequency</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Percent change in 28-day seizure frequency during the double-blind treatment period relative to the 6-week prospective baseline period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in caregiver global impression of change in attention</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Change in caregiver global impression of change in attention during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in caregiver global impression of change in target behavior</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Change in caregiver global impression of change in target behavior during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Clinical global impression of improvement during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arithmetic change in percent of seizure-free days of primary seizure types</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Arithmetic change in percent of seizure-free days of primary seizure types during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arithmetic change in longest seizure free interval, based on primary seizure types</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Arithmetic change in longest seizure free interval, based on primary seizure types during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver global impression of change in seizure intensity and duration</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Caregiver global impression of change in seizure intensity and duration during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>CDKL5 Deficiency Disorder</condition>
  <arm_group>
    <arm_group_label>Ganaxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo suspension 3x's /day for 17 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganaxolone</intervention_name>
    <description>active drug</description>
    <arm_group_label>Ganaxolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>inactive</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for ganaxolone)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed CDKL5 gene mutation, seizure onset by 1 year of age and lack of
             independent ambulation by 2 years of age

          -  Failure to control seizures despite 2 or more anti-seizure medications

          -  At least 16 seizures per 28 days of primary seizure types

          -  On a stable regimen of 0-4 anti-seizure medications (Vagus nerve stimulator, ketogenic
             diet, and modified Atkins diet do not count towards this limit)

          -  Additional Inclusion Criteria apply and can be discussed with study team

        Exclusion Criteria:

          -  Previous exposure to ganaxolone

          -  West Syndrome with hypsarrhythmia pattern on EEG or seizures predominantly of
             Infantile Spasms type

          -  Use of adrenocorticotropic hormone (ACTH), prednisone or other glucocorticoid or use
             of moderate or strong inducers or inhibitors of CYP3A4/5/7 are prohibited

          -  Use of tetrahydrocannabinol (THC) or cannabidiol (CBD) is prohibited during the
             double-blind phase, unless patient has a prescription of EpidiolexÂ®

          -  Exposure to any other investigational drug within 30 days or fewer than 5 half-lives
             prior to screening

          -  Plasma allopregnanolone-sulfate (Allo-S) levels greater than or equal to 6.0 ng/ml at
             screening visit

          -  Additional Exclusion Criteria apply and can be discussed with study team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Hulihan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>KrakÃ³w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Facility</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory seizures</keyword>
  <keyword>genetic pediatric encephalopathies</keyword>
  <keyword>epilepsy in children</keyword>
  <keyword>seizure disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

